Clofarabine-associated acute kidney injury and proteinuria

Pharmacotherapy

Volumn 31, Issue 9, 2011, Pages

  Kintzel, Polly E ^a   Visser, James A ^b   Campbell, Alan D ^c  

^a SPECTRUM HEALTH   (United States)

^b Renal Associates of West Michigan PC   (United States)

^c Pediatric Surgeons of West Michigan   (United States)

Author keywords

Adverse drug reaction; Clofarabine; Kidney failure; Renal insufficiency

Indexed keywords

ALLOPURINOL; CLOFARABINE; CREATININE; FUROSEMIDE; LISINOPRIL; PROTEIN; TOBRAMYCIN; VALACICLOVIR; ADENINE NUCLEOTIDE; ANTINEOPLASTIC AGENT; ARABINONUCLEOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; AGED; ARTICLE; CASE REPORT; COMORBIDITY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE SEVERITY; FAMILY; HEART LEFT VENTRICLE EJECTION FRACTION; HOME CARE; HOSPITALIZATION; HUMAN; INFORMED CONSENT; LEUKEMIA RELAPSE; MALE; PROTEINURIA; RATING SCALE; CHEMICALLY INDUCED DISORDER;

ACUTE KIDNEY INJURY; ADENINE NUCLEOTIDES; AGED; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; HUMANS; MALE; PROTEINURIA;

EID: 80052198696     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.9.923     Document Type: Article

References (24)

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Acute myeloid leukemia. Available from http://www.nccn.org/JNCCN/ toc/2011march.asp. Accessed June 10, 2011.
2. Al Ameri A, Koller C, Kantarjian H, et al. Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer 2010;116:93-7.
3. Lahoti A, Kantarjian H, Salahudeen AK, et al. Predictors and outcome of acute kidney injury in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer 2010;116:4063-8.
4. Burnett AK, Russell NH, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010;28:2389-95.
5. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged over 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008;112:1638-45.
6. Kantarjian H, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010;28:549-55.
7. Faderl S, Verstovsek S, Cortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006;108:45-51. (Pubitemid 43990611)
8. Genzyme Corporation. Clolar (clofarabine) product information. San Antonio, TX; 2009.
9. Zhenchuk A, Lotfi K, Juliusson G, Albertioni F. Mechanisms of anticancer action and pharmacology of clofarabine. Biochem Pharmacol 2009;78:1351-9.
10. Jeha S, Razzouk B, Rytting M, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol 2009;27:4392-7.
11. Karp JE, Ricklis RM, Balakrishnan K, et al. A phase I clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 2007;110:1762-9. (Pubitemid 47443886)
12. McGregor BA, Brown AW, Osswald MB, Savona MR. The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia. Am J Hematol 2009;84:228-30.
13. Kantarjian H, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003;21:1167-73. (Pubitemid 46594149)
14. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003;102:2379-86. (Pubitemid 37193573)
15. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45. (Pubitemid 12149145)
16. National Cancer Institute. Common terminology criteria for adverse events. Version 4. Available from http://evs.nci.nih.gov/ ftp1/CTCAE/About.html. Accessed February 10, 2011.
17. Bash LD, Selvin E, Steffes M, Coresh J, Astor BC. Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy. Arch Intern Med 2008;168:2440-7.
18. Blankstein R, Bakris GL. Renal hemodynamic changes in heart failure. Heart Fail Clin 2008;4:411-23.
19. Chiou WL, Hsu FH. Pharmacokinetics of creatinine in man and its implications in the monitoring of renal function and in dosage regimen modifications in patients with renal insufficiency. J Clin Pharmacol 1975;15:427-34.
20. Chambers HF. Aminoglycosides. In: Brunton LL, ed. Goodman & Gilman's the pharmacological basis of therapeutics, 11th ed. Available from http://www.accessmedicine.com/content.aspx?aID=949068. Accessed November 1, 2010.
21. Jackson EK. Renin and angiotensin. In: Brunton LL, ed. Goodman & Gilman's the pharmacological basis of therapeutics, 11th ed. Available from http://www.accessmedicine.com/content.aspx?aID=944099. Accessed November 1, 2010.
22. Jackson EK. Diuretics. In: Brunton LL, ed. Goodman & Gilman's the pharmacological basis of therapeutics, 11th ed. Available from http://www.accessmedicine.com/content. aspx?aID=943427. Accessed November 1, 2010.
23. Hayden FG. Antiviral agents (nonretroviral). In: Brunton LL, ed. Goodman & Gilman's the pharmacological basis of therapeutics, 11th ed. Available from http://www.access medicine.com/content.aspx?aID=950476. Accessed November 1, 2010.
24. McEvoy GK, ed. Allopurinol. In: AHFS drug information 2010. Bethesda, MD: American Society of Health-System Pharmacists, 2010:3662-6.